Treatment of Helicobacter pylori

Bibliography

• BLASER MJ: Hypothesis on the pathogenesis and natural history of Helicobacter pylori induced inflammation. Gastroenterology (1992) 102:720–727.
   PubMed Web of Science ®Google Scholar
• HAWKEY CJ: Non-steroidal anti-inflammatory drugs and peptic ulcers. Br. Med. 1 (1990) 300:278–284.
   Google Scholar
• Haubrich W, Snaffer F (Eds.), WB Saunders Co. (1994).
   Google Scholar
• HAWKEY CJ: Controversies in management - eradication of Helicobacter pylori should be pivotal in managing peptic ulceration. Eradication largely prevents relapse. Br. Med. 1 (1994) 309:1570–1571.
   Google Scholar
• THUS JC, KUIPERS EJ, VAN ZWET AA, PENA AS, DE GRAAFF J: Treatment of Helicobacter pylori infections. Quart. 1 Med. (1995) 88:369–389.
   Web of Science ®Google Scholar
• CARRICK J, LEE A, HAZELL S, RALSTON M, DASKAOPOULOS G: Campylobacter pylori, duodenal ulcer and gastric metaplasia: possible role of functional heterotopic tissue ulcerogenesis. Gut (1989) 30:709–797.
   Google Scholar
• GOODMAN KJ, CORREA P: The transmission of Helicobacter pylori. A critical review of the evidence. Int. 1 EpidemioL (1995) 24:875–887.
   PubMed Web of Science ®Google Scholar
• AXON ATR: The transmission of Helicobacter pylori: which theory fits the facts Eur. GastroenteroL Hepatol. (1996) 8:1–2.
   Google Scholar
• GRAHAM DY, KLEIN PD, EVANS DJ, Jr. et al.: Campylobacter pylori detected non-invasively by the [13C] urea breath test. Lancet (1987) 1:1174–1177.
   PubMed Web of Science ®Google Scholar
• LOGAN RPH, DILL S, BAUER FE, et al.: The European [13C] urea breath test for the detection of Helicobacter pylori. Eur. I GastroenteroL HepatoL (1991) 3:915–921.
   Web of Science ®Google Scholar
• CRABTREE JE, WYATT JI, TREJDOSIEWIC KL, et al.: Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. 1 Clin. PathoL (1994) 47:61–66.
   Google Scholar
• MOSS SF, LEGON S, DAVIES J, CALAM J: Cytokine gene expression in Helicobacter pylori associated antral gastritis. Gut (1994) 35:1567–1570.
   PubMed Web of Science ®Google Scholar
• NOACH LA, BOSMA B, JANSEN J, et al.: Mucosal tumour necrosis factor-a, interleukin-10 and interleukin-8 production in patients with Helicobacter pylori infection. Scand. I GastroenteroL (1994) 29:425–429.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLAN JM, SETH R, JENKINS DJ, ROBINS AR, HAWKEY CJ: Increased interleukin-8 mRNA in gastric epithelium with Helicobacter pylori infection, detected by quantitative chemi-luminescent assay of RT-PCR product. Gut (Submitted).
   Google Scholar
• HUDSON N, BALSITIS M, EVERITT S, HAWKEY CJ: Enhanced gastric mucosal leukotriene B4 synthesis in patients on long-standing non-steroidal anti-inflammatory drugs. Gut (1993) 34:742–747.
   PubMed Web of Science ®Google Scholar
• MCCOLL KEL, EL-NUJUMI AM, CHITTAJALLU RS, et al.: A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut (1993) 34:762–768.
   PubMed Web of Science ®Google Scholar
• MOSS SF, LEGON S, BISHOP AE, POLAK JM, CALAM J: Effect of Helicobacterpylori on gastric somatostatin in duodenal ulcer disease. Lancet (1992) 340:930–932.
   PubMed Web of Science ®Google Scholar
• BLASER MJ, PARSONNET J: Parasitism by the 'slow' bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. 1 Clin. Invest. (1994) 94:4–8.
   PubMed Web of Science ®Google Scholar
• ELOMAR EM, PENMAN ID, SPENCE E, ARDILL J, MCCOLL K: The GRP test - a new clinical test of acid secretion reproducibility data. Eur. I GastroenteroL HepatoL (1994) 6:417–421.
   Web of Science ®Google Scholar
• COURILLON-MALLET A, LAUNAY JM, ROUCAYROL AM, et al.: Helicobacter pylori infection: physiopathologic implication of Na-methyl histamine. Gastroenterology (1995) 108:959–966.
   PubMed Web of Science ®Google Scholar
• LEE A, DIXON MF, DANON SJ, et al.: Local acid production and Helicobacter pylori - a unifying hypothesis of gastroduodenal disease. Eur. I GastroenteroL HepatoL (1995) 7:461–465.
   PubMed Web of Science ®Google Scholar
• PARSONNET J, FRIEDMAN GD, VANDERSTEEN DP, et al.: Helicobacter pylori infection and the risk of gastric carcinoma. New Engl. 1 Med. (1991) 325:1127–1131.
   Google Scholar
• NOMURA A, STEMMERMANN GN, CHYOU PH, et al.: Helkobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. New Engl. 1 Med. (1991) 325:1132–1136.
   Google Scholar
• FORMAN D, NEWELL DG, FULLERTON F, et al. : Association between infection with Helicobacter pylori and risk of gastric cancer. Evidence from a prospective investigation. Br. Med. 1 (1991) 302:1302–1305.
   Google Scholar
• NIH CONSENSUS DEVELOPMENT PANEL: Helicobacter pylori in peptic ulcer disease. JAMA (1994) 272:65–69.
   PubMed Web of Science ®Google Scholar
• HENTSCHEL E, BRANDSTATTER G, DRAGOSICS B, et al.: Effect of ranitidine and amoxycillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. New Engl. 1 Med. (1993) 328:308–312.
   Google Scholar
• GRAHAM DY, LEW GM, KLEIN PD, et al.: Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomised controlled study. Ann. Intern Med. (1992) 116:705–708.
   PubMed Web of Science ®Google Scholar
• CUTLER AF, SCHUBERT TT: Long-term Helicobacter pylori recurrence after successful eradi-cation with triple therapy. Am. I Gastroenterol. (1993) 88:1359–1361.
   PubMed Web of Science ®Google Scholar
• LABENZ J, BORSCH G: Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. Am. I GastroenteroL (1994) 89:1785–1788.
   PubMed Web of Science ®Google Scholar
• TYTGAT GNJ: No Helicobacter pylori, no Helicobacter pylori associated peptic ulcer disease. Aliment. PharmacoL Ther. (1995) 9:39–42.
   PubMed Web of Science ®Google Scholar
• BORODY T, COLE P, NOONAN P, et al.: Recurrence of duodenal ulcers and Campylobacter pylori infection after eradication. Med. I AusL (1989) 151:431–435.
   PubMed Web of Science ®Google Scholar
• FORBES GM, GLASER ME, CULLEN DJE, et al.: Duodenal ulcer treated with Helicobacter pylori eradication - 7 year follow up. Lancet (1994) 343:258–260.
   PubMed Web of Science ®Google Scholar
• GRAHAM DY, HEPPS KS, RAMIREZ FC, LEW GM, SAEED ZA: Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand. I GastroenteroL (1993) 28:939–942.
   PubMed Web of Science ®Google Scholar
• LABNEZ J, BORSCH G: Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion (1994) 55:19–23.
   PubMed Web of Science ®Google Scholar
• MCCOLL KEL: The role of Helicobacter pylori eradication in the management of acute bleeding peptic ulcer. Eur. I GastroenteroL Hepatol. (1995) 7:753–755.
   PubMed Web of Science ®Google Scholar
• LABNEZ J, TILLENBURG B, PEITZ U, STOLTE M, BORSCH G: Peptic ulcer haemorrhage. How to prevent further bleeding episodes. Leber. Magen. Darm. (1995) 25:27–33.
   PubMed Web of Science ®Google Scholar
• LOGAN RPH, GUMMETT PA, MISIEWICZ JJ, et al: One week eradication regimen for Helico-bacter pylori. Lancet (1991) 338:1249–1252.
   PubMed Web of Science ®Google Scholar
• GRAHAM DY, LEW GM, EVANS DG, EVANS DJ, KLEIN PD: Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing: a randomised controlled trial. Ann. Intern. Med. (1991) 115:266–269.
   PubMed Web of Science ®Google Scholar
• HOSKING SW, LING TX, CHUNG SC, YUNG MY, CHENG AFB: Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: a randomised, controlled trial. Lancet (1994) 343(8896):508–510.
   PubMed Web of Science ®Google Scholar
• CULLEN DJE, HAWKEY GM, HUMPHRIES J, et al: Role of non-steroidal anti-inflammatory drugs and Helicobacter pylori in bleeding peptic ulcer. Gastroenterology (1994) 106:A66.
   Google Scholar
• HUDSON N, BALSITIS M, FILIPOWICZ B, HAWKEY CJ: Effect of Helicobacter pylori colonisa-tion on gastric mucosal eicosanoid synthesis in patients taking non steroidal anti inflammatory drugs. Gut (1993) 34:748–751.
   PubMed Web of Science ®Google Scholar
• TALLEY NJ: A critique of therapeutic trials in Helicobacter pylori positive functional dyspepsia. Gastroenterology (1994) 106:1174–1183.
   PubMed Web of Science ®Google Scholar
• MCCARTHY C, PATCHETT S, COLLINS RM, et al: Long-term prospective study of Helicobacter pylori in nonulcer dyspepsia. Dig. Dis. Sci. (1995) 40:114–119.
   PubMed Web of Science ®Google Scholar
• VERDU EF, ARMSTRONG D, IDSTROM JP, et al: Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut (1995) 37:743–748.
   PubMed Web of Science ®Google Scholar
• JUSTIN TA, STEELE RJC: Helicobacter infection is associated with oesophagitis in patients with Barrett's oesophagus. Gut (1994) 35\(Suppl. 2):55.
   Google Scholar
• KUIPERS EJ, UYTERLINDE AM, PENA AS, et al.: Increase of Helicobacter pylori associated corpus gastritis during acid suppressive therapy - implications for long term safety. Am. GastroenteroL (1995) 90:1401–1406.
   PubMed Web of Science ®Google Scholar
• KUIPERS EJ, PEREZ-PEREZ GI, MEUVVISSEN SGM, BLASER MJ: Helicobacter pylori and atrophic gastritis - importance of the cagA status. J. Natl. Cancer Inst. (1995) 87:1777–1780.
   PubMed Web of Science ®Google Scholar
• WOTHERSPOON AC, DOGLIONI C, DISS TC, et al.: Regression of primary low grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet (1993) 342:575–577.
   Google Scholar
• ISAACSON PG: Gastric lymphoma and Helicobacter pylori. New Engl. I Med. (1994) 330:1130–1131.
   Google Scholar
• PARSONNET J, HANSEN S, RODRIGUEZ L, et al.: Helicobacter pylori infection and gastric lymphoma. New Engl. I Med. (1994) 330(18):1267–1271.
   PubMed Web of Science ®Google Scholar
• BAYERDORFFER E, RITTER MM, HATZ R, et al.: Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori - is Helicobacter pylori a pathogenic factor in Menetrier's disease Gut (1994) 35:701–704.
   Google Scholar
• VAN ZANTEN SJO, GOLD1E J, HOLLINGS WORTH J, et al.: Secretion of intravenously admin-istered antibiotics in gastric juice; implications for management of Helicobacter pylori. I Clin. PathoL (1992) 45:225–227.
   PubMed Web of Science ®Google Scholar
• BAZZOLI F, ZAGARI RM, FOSSI S, et al.: Short term low-dose triple therapy for eradication of Helicobacter pylori. Eur. I GastroenteroL HepatoL (1994) 6:773–777.
   Web of Science ®Google Scholar
• LIND T, VELDHUYZEN ZV, UNGE P, et al.: The MACH 1 study: optimal one week treatment for H. pylori defined Gut (1995) 37\(Supp1.1):A15.
   Google Scholar
• WALSH JII, PETERSON WL: The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. New Engl. I Med. (1995) 333:984–991.
   PubMed Web of Science ®Google Scholar
• GRAYSON ML, ELIOPOULOS GM, FERRARO MJ, MOELLERING RC: Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur. I Clin. MicrobioL Infect. Dis. (1989) 8:888–889.
   PubMed Web of Science ®Google Scholar
• PAULSEN O, HOGLUND P, WALDER M: No effects of omeprazole induced hypoacidity on the bioavailability of amoxycillin or bacampicillin. Scand. I Infect. Dis. (1989) 21:219–223.
   PubMed Web of Science ®Google Scholar
• HIRSCHL AM, HIRSCHL MM, ROTTER ML: Comparison of 3 methods for the determination of the sensitivity of Helicobacter pylori to metronidazole. I Antimicrob. Chemother. (1993) 32:45–49.
   PubMed Web of Science ®Google Scholar
• SMITH MA, EDWARDS DI: Redox potential and oxygen concentration as factors in the suscep-tibility of Heficobacterpy/ori to nitroheterocyclic drugs. J. Antimicrob. Chemother. (1995) 35:751–764.
   PubMed Web of Science ®Google Scholar
• CEDERBRANT C, KAHLMETER G, LJUNGH A: Proposed mechanisms for metronidazole resistance in Helicobacter pylori. I Antimicrob. Chemother. (1992) 29:115–120.
   PubMed Web of Science ®Google Scholar
• CEDERBRANT G, KAHLMETER G, SCHALEN C, KANIME C: Additive effect of darithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or ome-prazole against Helicobacter pylori. I Antimicrob. Chemother. (1994) 34:1025–1029.
   PubMed Web of Science ®Google Scholar
• LOGAN RPH, BARDHANKD, CELESTIN LR: Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomised double-blind multi-center trial of omeprazole with or without darithromycin. Aliment. Pharmacol. Ther. (1995) 9:417–424.
   PubMed Web of Science ®Google Scholar
• GRAHAM DY: Clarithromycin for treatment of Helicobacter pylori infections. Eur. I Gastroen-teroL Hepatol. (1995) 7:55–58.
   Web of Science ®Google Scholar
• VERSALOVIC J, KIBLER K, SMALL S, et al.: Molecular basis of clarithromycin resistance in Helicobacter pylori. Gastroenterology (1995) 108:A251.
   Google Scholar
• SUERBAUM S, LEYING H, KLEMM K, OPFERKUCH W: Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori [letter]. Eur. I Clin. MicrobioL Infect. Dis. (1991) 10:92–93.
   PubMed Web of Science ®Google Scholar
• PETERSON WL, GRAHAM DY, MARSHALL B, et al.: Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomised double blind trial. Am. I GastroenteroL (1993) 88(11):1860–1864.
   PubMed Web of Science ®Google Scholar
• IVVAHI T, SATOH H, NAKAO M, et al.: Lansoprazole, a novel benzimidazole proton pump inhibitor and its related compounds have selective activity against Helicobacter pylori. Antimicrob. Agents Chemother. (1991) 35:490–496.
   PubMed Web of Science ®Google Scholar
• BUGNOLI M, BAYELI PF, RAPPUOLI R, et al.: Inhibition of Helicobacter pylori urease by omeprazole. Eur. I GastroenteroL HepatoL (1993) 5:683–685.
   Web of Science ®Google Scholar
• WILDE MI, MCTAVISH D: Omeprazole - an update of its pharmacology and therapeutic use in acid related disorders. Drugs (1994) 48:91–132.
   PubMed Web of Science ®Google Scholar
• YOUSFI MM, EL-ZIMAITY HM, AL-ASSI MT, et al.: Metronidazole, omeprazole and darithromycin; an effective combination therapy for Helicobacter pylori infection. Aliment. Pharmacol. Ther. (1995) 9:209–212.
   PubMed Web of Science ®Google Scholar
• Balows A (Ed.), Am. Soc. Microbiol., Washington DC (1990):1073.
   Google Scholar
• CHIBA N, RAO By, RADEMAKER JVV, HUNT RH: Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am. I GastroenteroL (1992) 87:1716–1727.
   PubMed Web of Science ®Google Scholar
• VAN CAEKENBERGHE DL, BREYSSENS J: In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylor). Antimi-crob. Agents Chemother. (1987) 31:1429–1430.
   Google Scholar
• NVVOKOLO CU, LEWIN JF, HUDSON M, POUNDER RE: Trans mucosal penetration of bismuth particles in the human stomach. Gastroenterology (1992) 102:163–167.
   PubMed Web of Science ®Google Scholar
• SADLER PJ, SUN HZ: Ranitidine bismuth (III) citrate. I Chem. Soc. Dalton Trans. (1995) 9:1395–1401.
   Google Scholar
• KOCK KM, KERR BM, GODDING AE, DAVIS BC Pharmacokinetics of bismuth and ranitidine following multiple doses of ranitidine bismuth citrate. Br. I Clin. Pharmacol. (1996) 42(2):207–211.
   PubMed Web of Science ®Google Scholar
• PETERSON WL, CIOCIOLA AA, SYKES DL, et al.: Ranitidine bismuth citrate plus clarithromy-cin is effective for healing duodenal ulcers, eradicating Helicobacter pylori and reducing ulcer recurrence. Aliment. Pharmacol. Ther. (1996) 10(3):251–261.
   PubMed Web of Science ®Google Scholar
• MCCOLM AA, MCLAREN A, KLINKERT G, et al.: Ranitidine bismuth citrate - a novel anti ulcer agent with different physicochemical characteristics and improved biological activity to a bis-muth citrate ranitidine admixture. Aliment. Pharmacol. Ther. (1996) 10(3):241–250.
   PubMed Web of Science ®Google Scholar
• DE BOER W, DRIESSEN W, JANSZ A, TYTGAT G: Effect of acid suppression on efficacy of treatment of Helicobacter pylori infection. Lancet (1995) 345:817–820.
   PubMed Web of Science ®Google Scholar
• COGHLAN JG, HUMPHRIES H, DOOLEY C, et al.: Campylobacter pylori and recurrence of duodenal ulcers - a 12 month follow up study. Lancet (1987) 2:1109–1111.
   PubMed Web of Science ®Google Scholar
• MARSHALL BJ, GOODWIN SC, WARREN JR, et al.: Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet (1988) 2:1437–1442.
   PubMed Web of Science ®Google Scholar
• RAUVVS EAJ, TYTGAT GNJ: Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet (1990) 335:1233–1235.
   PubMed Web of Science ®Google Scholar
• PENSTONJG: Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment. PharmacoL Ther. (1994) 8:369–389.
   PubMed Web of Science ®Google Scholar
• TYTGAT CNJ: Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment. Pharmacol. Ther. (1994) 8:359–368.
   PubMed Web of Science ®Google Scholar
• BAYERDORFFER E: High dose omeprazole treatment combined with amoxycillin eradicates Helicobacter pylori. Eur. I GastroenteroL HepatoL (1992) 4:697–702.
   Web of Science ®Google Scholar
• LABENZ J, GYENES E, RUHL GH, BORSCH G: Amoxycillin plus omeprazole versus triple therapy for eradication ofHelkobacter pylori in duodenal ulcer disease; a prospective randomised and controlled study. Gut (1993) 34:1167–1170.
   PubMed Web of Science ®Google Scholar
• BAYERDORFFER E, SCHULZ H, SIMON T, et al.: Double blind trial of lansoprazole and amoxycillin vs. lansoprazole and darithromycin for cure of Helicobacter pylori infection in duodenal ulcer patients. Gastroenterology (1995) 108:A57.
   Google Scholar
• LABENZ J, STOLTE M, PEITZ U, et al: Omeprazole/amoxycillin versus triple therapy for Helicobacterpylori in duodenal ulcer disease -2 year follow up of a prospective randomized study. Seitschrift fur Gastroenterologie (1995) 33:590–593.
   PubMed Web of Science ®Google Scholar
• GRAHAM KS, MALATY H, ELZIMAITY HMT, et al.: Variability with omeprazole amoxycillin combinations for treatment of Helicobacter pylori infection. Am. I Gastroenterol. (1995) 90:1415–1418.
   PubMed Web of Science ®Google Scholar
• LABENZ J, STOLTE M, DOMIAN C, BERTRANIS J, BORSCH G: High dose omeprazole plus amoxycillin or darithromycin cures Helicobacter pylori infection in duodenal ulcer disease. Digestion (1995) 56:14–20.
   PubMed Web of Science ®Google Scholar
• GODDARD AF, LOGAN RPH: One week low dose triple therapy: new standards for Helicobacter pylori treatment. Eur. I GastroenteroL Hepatol. (1995) 7:1–3.
   PubMed Web of Science ®Google Scholar
• LABENZ J, STOLTE M, RUHL GH, et al: One week low dose triple therapy for the eradication of Helicobacter pylori infection. Eur. I GastroenteroL HepatoL (1995) 7:9–11.
   PubMed Web of Science ®Google Scholar
• MOAYYEDI P, SAHAY P, TOMPKINS DS, AXON ATR: Efficacy and optimum dose of omepra-zole in a new 1-week triple therapy regimen to eradicate Helkobacter pylori. Eur. I GastroenteroL HepatoL (1995) 7:835–840.
   PubMed Web of Science ®Google Scholar
• CAYLA R, DEMASCAREL A, ZERBIB F, et al: High dose of lansoprazole plus amoxycillin versus high dose of lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori infection. Gastroenterology (1995) 108:A68.
   Web of Science ®Google Scholar
• LAMOULIATTE H: Adjuvant therapy for Helicobacter pylori eradication - role of lansoprazole in clinical studies. I Gun. GastroenteroL (1995) 20:28–31.
   Web of Science ®Google Scholar
• TAKIMOTO T, IDO K, TANIGUCHI Y et al.: Efficacy of lansoprazole in eradication of Helico-bacter pylori. J. Clin. Gastroenterol. (1995) 20:121–124.
   Google Scholar
• TONGE KA, GODDARD AF, LOGAN RPH, et al.: Eradication of Helicobacter pylori using darithromycin, omeprazole and amoxycillin for one week. Gastroenterology (1995) 108:242.
   PubMed Web of Science ®Google Scholar
• SALANDIN S, BATTAGLIA G, DALBO N, et al.: Clarithromycin for the cure of Helicobacter pylori infection. One or 2 weeks of treatment. Gastroenterology (1995) 108:A207.
   Google Scholar
• BUCKLEY M, KEATING S, XIA H, et al.: Omeprazole plus one or 2 antibiotics to eradicate Helicobacter pylori. Gastroenterology (1995) 108:A63.
   Google Scholar
• LABENZ J, ADAMEK RJ, STOLTEM et al. : Efficacy and safety of 2 simple one week triple therapy schedules for Helicobacter pylori. Gastroenterology (1995) 108:A140.
   Google Scholar
• LABENZ J, PEITZ U, TILLENBURG B, et al.: Short term triple therapy with pantoprazole, darithromycin and metronidazole for eradication of Helicobacter pylori. Leber. Magen. Darm. (1995) 25:122–127.
   PubMed Web of Science ®Google Scholar
• JAUP BH, NORRBY A: Low dose short term triple therapy for cure ofHelicobacter pylori infection and healing of peptic ulcers. Am. J. GastroenteroL (1995) 90:943–945.
   PubMed Web of Science ®Google Scholar
• GODDARD AF, LOGAN RPH, LAWES S, HAWKEY CJ, SPILLER RC: Metronidazole or tinida-zole with omeprazole and darithromycin for the eradication of H. pylori. Gut (1996) 38(S1):A1 3.
   Google Scholar
• GRAHAM DY, LEW GM, MALATY HM, et al.: Factors influencing the eradication of Helkobacter pylori with triple therapy. Gastroenterology (1992) 102:493–496.
   PubMed Web of Science ®Google Scholar
• TOMB JF, SUTTON G, GLODEK A, et al.: The complete DNA sequence of the Helicobacter pylori genome. Gut (1996) 39(52):A3.
   Google Scholar
• ATHERTON JA, COVER TL, BLASER MJ: Helicobacter pylori: thoughts on the implications of infection and on vaccine development. The Jordan Report - National Institute ofAllergy & Infectious Diseases (1995):60–62.
   Google Scholar
• ATHERTON JC, CAO P, PEEK RM, Jr. et al.: Mosaicism in vacuolating cytotoxin alleles of H. pylori. Association of specific VacA types with cytotoxin production and peptic ulceration. J. Biol. Chem. (1995) 270(30):17771–17777.
   PubMed Web of Science ®Google Scholar
• ODENBREIT S, TILL M, HAAS R: Optimized BlaM-transposon shuttle mutagenesis of Helico-bacter pylori allows the identification of novel genetic loci involved in bacterial virulence.
   Google Scholar
• PEEK RM, THOMPSON SA, ATHERTON JC, BLASER MJ, MILLER GG: Expression of a novel ulcer-associated Helkobacter pylori gene, iceA following adherence to gastric epithelial cells. Gastroenterology (1996) 110(4):225.
   Google Scholar
• TUMMURU MKR, SHANNA SA, BLASER MJ: Helicobacter pylori picB a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells. Ma Microbiol. (1995) 18(5):867–876.
   PubMed Web of Science ®Google Scholar
• BLASER MJ: Role of VacA and the CagA locus of Helicobacter pylori in human disease. Aliment. Pharmacol. Ther. (1996) 10\(Suppl. 1):73–77.
   Google Scholar
• KHAN S, SPUDICH JL, MCCRAY JA, TRENTHAM DR: Chemotactic signal integration in bacteria. Proc. Natl. Acad. Sci. USA (1995) 92(21):9757–9761.
   PubMed Web of Science ®Google Scholar
• FORBES KJ, FANG Z, PENNINGTON TH: Allelic variation in the Helicobacter pylori flagellin genes flaA and flaB: its consequences for strain typing schemes and population structure. Epidemiol. Infect. (1995) 114(2):257–266.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Nisin trials for H. pylori. Scrip (1996) 2122:22.
   Google Scholar
• KIMURA K, DO K, KIHIRA K, et al.: An endoscopic topical therapy for the treatment of Helicobacter pylori infection. Gastroenterology (1995) 108(4):A210.
   Google Scholar
• GODDARD AF, JESSA MJ, BARRETT DA, et al.: Effect of omeprazole on the distribution of metronidazole, amoxicillin and clarithromycin in human gastric juice. Gastroenterology (1996) 111(2):358–367.
   PubMed Web of Science ®Google Scholar
• PATEL VR, AMJI MM: Preparation and characterization of freeze dried chitosanpoly hydrogels for site specific antibiotic delivery in the stomach. Pharmaceut. Res. (1996) 13(4):588–593.
   PubMed Web of Science ®Google Scholar
• EXNER MM, DOIG P, TRUST TJ, HANCOCK REW: Isolation and characterization of a family of porin proteins from Helicobacter pylori. Infect. Immun. (1995) 63(4):1567–1572.
   PubMed Web of Science ®Google Scholar
• MOORE RA, BECKTHOLD B, WONG S, KUREISHI A, BRYAN LE: Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin resistant mutants of Helicobacter pylon. Antimi-crob. Agents Chemother. (1995) 39(1):107–111.
   PubMed Web of Science ®Google Scholar
• DOIG P, EXNER MM, HANCOCK REW, TRUST TJ: Isolation and characterization of a conserved porin protein from Helicobacter pylori. J. Bacteria (1995) 177(19):54475452.
   Google Scholar
• GHIARA P, MICHETTI P: Development of a vaccine. Curr. Opin. Gastroentera (1995) 11(S1):52–56.
   Google Scholar
• MARCHETTI M, ARICO B, BURRONI D, et al.: Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science (1995) 267(5204):1655–1658.
   PubMed Web of Science ®Google Scholar
• LEE A, BUCK F: Vaccination and mucosal responses to Helicobacter pylori infection. Aliment. Pharmacol. Ther. (1996) 10\(Suppl. 1):129–138.
   Google Scholar
• PHADNIS SH, PARLOW MH, LEVY M, et al.: Surface localization of Helicobacter pylori urease and a heatshock protein homolog requires bacterial autolysis. Infect. Immun. (1996) 64(3):905–912.
   PubMed Web of Science ®Google Scholar
• SELHNAN S, BLANCHARD TG, NEDRUD JG, CZINN SJ: Vaccine strategies for prevention of Helicobacter pylori infection. Eur. I Gastroentera Hepata (1995) 7\(Suppl. 1):S1–56.
   Google Scholar
• ANONYMOUS: Neose begins clinical development of H. pylori drug. Scrip (1995) 2015:24.
   Google Scholar